1. The Alopecia Areata Severity and Morbidity Index (ASAMI) Study
- Author
-
Group, ASAMI Consensus Survey Study, Moussa, Anthony, Bennett, Michaela, Wall, Dmitri, Meah, Nekma, York, Katherine, Bokhari, Laita, Asfour, Leila, Rees, Huw, Abraham, Leonardo Spagnol, Asz-Sigall, Daniel, Basmanav, Fitnat Buket, Bergfeld, Wilma, Betz, Regina C, Bhoyrul, Bevin, Blume-Peytavi, Ulrike, Callender, Valerie, Chitreddy, Vijaya, Combalia, Andrea, Cotsarelis, George, Craiglow, Brittany, Dhurat, Rachita, Donovan, Jeff, Doroshkevich, Andrei, Eisman, Samantha, Farrant, Paul, Ferrando, Juan, Gadzhigoroeva, Aida, Green, Jack, Grimalt, Ramon, Harries, Matthew, Hordinsky, Maria, Irvine, Alan, Jolliffe, Victoria, Kaiumov, Spartak, King, Brett, Lee, Joyce, Lee, Won-Soo, Li, Jane, Lortkipanidze, Nino, McMichael, Amy, Mesinkovska, Natasha Atanaskova, Messenger, Andrew, Mirmirani, Paradi, Olsen, Elise, Orlow, Seth J, Ovcharenko, Yuliya, Piraccini, Bianca Maria, Pirmez, Rodrigo, Rakowska, Adriana, Reygagne, Pascal, Rudnicka, Lidia, Corralo, David Saceda, Senna, Maryanne, Shapiro, Jerry, Sharma, Pooja, Siliuk, Tatiana, Starace, Michela, Suchonwanit, Poonkiat, Takwale, Anita, Tosti, Antonella, Vañó-Galván, Sergio, Visser, Willem I, Vogt, Annika, Wade, Martin, Yip, Leona, Zhou, Cheng, and Sinclair, Rodney
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Autoimmune Disease ,Good Health and Well Being ,Humans ,Alopecia Areata ,Consensus ,Quality of Life ,Alopecia ,Morbidity ,ASAMI Consensus Survey Study Group ,Oncology and Carcinogenesis - Abstract
ImportanceCurrent measures of alopecia areata (AA) severity, such as the Severity of Alopecia Tool score, do not adequately capture overall disease impact.ObjectiveTo explore factors associated with AA severity beyond scalp hair loss, and to support the development of the Alopecia Areata Severity and Morbidity Index (ASAMI).Evidence reviewA total of 74 hair and scalp disorder specialists from multiple continents were invited to participate in an eDelphi project consisting of 3 survey rounds. The first 2 sessions took place via a text-based web application following the Delphi study design. The final round took place virtually among participants via video conferencing software on April 30, 2022.FindingsOf all invited experts, 64 completed the first survey round (global representation: Africa [4.7%], Asia [9.4%], Australia [14.1%], Europe [43.8%], North America [23.4%], and South America [4.7%]; health care setting: public [20.3%], private [28.1%], and both [51.6%]). A total of 58 specialists completed the second round, and 42 participated in the final video conference meeting. Overall, consensus was achieved in 96 of 107 questions. Several factors, independent of the Severity of Alopecia Tool score, were identified as potentially worsening AA severity outcomes. These factors included a disease duration of 12 months or more, 3 or more relapses, inadequate response to topical or systemic treatments, rapid disease progression, difficulty in cosmetically concealing hair loss, facial hair involvement (eyebrows, eyelashes, and/or beard), nail involvement, impaired quality of life, and a history of anxiety, depression, or suicidal ideation due to or exacerbated by AA. Consensus was reached that the Alopecia Areata Investigator Global Assessment scale adequately classified the severity of scalp hair loss.Conclusions and relevanceThis eDelphi survey study, with consensus among global experts, identified various determinants of AA severity, encompassing not only scalp hair loss but also other outcomes. These findings are expected to facilitate the development of a multicomponent severity tool that endeavors to competently measure disease impact. The findings are also anticipated to aid in identifying candidates for current and emerging systemic treatments. Future research must incorporate the perspectives of patients and the public to assign weight to the domains recognized in this project as associated with AA severity.
- Published
- 2024